Drug Information
Drug General Information | |||||
---|---|---|---|---|---|
Drug ID |
D0BN1U
|
||||
Former ID |
DIB020298
|
||||
Drug Name |
M&B 28767
|
||||
Synonyms |
M&B-28767; Dpt-prostaglandin E1
|
||||
Drug Type |
Small molecular drug
|
||||
Indication | Discovery agent | Investigative | [539214] | ||
Structure |
Download2D MOL |
||||
Formula |
C22H30O5
|
||||
InChI |
InChI=1S/C22H30O5/c23-18(16-27-19-8-4-3-5-9-19)14-12-17-13-15-21(24)20(17)10-6-1-2-7-11-22(25)26/h3-5,8-9,12,14,17-18,20,23H,1-2,6-7,10-11,13,15-16H2,(H,25,26)/b14-12+/t17-,18+,20+/m0/s1
|
||||
InChIKey |
NZGFSDWJUZOAAX-KAVAACISSA-N
|
||||
PubChem Compound ID | |||||
PubChem Substance ID | |||||
Target and Pathway | |||||
Target(s) | Thromboxane A2 receptor | Target Info | Agonist | [525673] | |
Prostaglandin E2 receptor, EP4 subtype | Target Info | Agonist | [534478] | ||
Prostaglandin F2-alpha receptor | Target Info | Agonist | [534478] | ||
Prostaglandin E2 receptor, EP1 subtype | Target Info | Agonist | [534478] | ||
Prostaglandin E2 receptor EP3 subtype | Target Info | Agonist | [534478] | ||
Prostaglandin E2receptor, EP2 subtype | Target Info | Agonist | [534595] | ||
KEGG Pathway | Calcium signaling pathway | ||||
Neuroactive ligand-receptor interaction | |||||
Platelet activationhsa04080:Neuroactive ligand-receptor interaction | |||||
Inflammatory mediator regulation of TRP channels | |||||
Renin secretion | |||||
Pathways in cancerhsa04020:Calcium signaling pathway | |||||
Neuroactive ligand-receptor interactionhsa04020:Calcium signaling pathway | |||||
cAMP signaling pathway | |||||
Regulation of lipolysis in adipocytes | |||||
Pathways in cancerhsa04024:cAMP signaling pathway | |||||
Pathways in cancer | |||||
PANTHER Pathway | PI3 kinase pathway | ||||
Reactome | Prostanoid ligand receptors | ||||
G alpha (q) signalling events | |||||
G alpha (12/13) signalling events | |||||
Thromboxane signalling through TP receptorR-HSA-391908:Prostanoid ligand receptors | |||||
G alpha (s) signalling eventsR-HSA-391908:Prostanoid ligand receptors | |||||
G alpha (q) signalling eventsR-HSA-391908:Prostanoid ligand receptors | |||||
G alpha (i) signalling eventsR-HSA-391908:Prostanoid ligand receptors | |||||
G alpha (s) signalling events | |||||
WikiPathways | GPCRs, Class A Rhodopsin-like | ||||
Gastrin-CREB signalling pathway via PKC and MAPK | |||||
Small Ligand GPCRs | |||||
Signal amplification | |||||
GPCR ligand binding | |||||
GPCR downstream signalingWP98:Prostaglandin Synthesis and Regulation | |||||
Vitamin D Receptor Pathway | |||||
GPCR downstream signaling | |||||
GPCRs, OtherWP98:Prostaglandin Synthesis and Regulation | |||||
Ovarian Infertility Genes | |||||
References | |||||
Ref 525673 | The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs. Biochim Biophys Acta. 2000 Jan 17;1483(2):285-93. | ||||
Ref 534478 | Ligand binding specificities of the eight types and subtypes of the mouse prostanoid receptors expressed in Chinese hamster ovary cells. Br J Pharmacol. 1997 Sep;122(2):217-24. | ||||
Ref 534595 | Molecular cloning and characterization of the four rat prostaglandin E2 prostanoid receptor subtypes. Eur J Pharmacol. 1997 Dec 11;340(2-3):227-41. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.